UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1425-3
Program Prior Authorization/Notification
Medication * Omvoh™ (mirikizumab-mrkz)
*This program applies to the subcutaneous formulation of Omvoh.
P&T Approval Date 1/2024, 1/2025, 3/2025
Effective Date 5/1/2025
1. Background:
Omvoh (mirikizumab-mrkz) is an interleukin-23 antagonist indicated for the treatment of
moderately to severely active ulcerative colitis in adults and moderately to severely active
Crohn's disease in adults.
2. Coverage Criteriaa:
A. Ulcerative Colitis (UC)
1. Initial Authorization for Maintenance Dosing
a. Omvoh will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active ulcerative colitis
-AND-
(2) Patient is not receiving Omvoh in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel (etanercept),
Entyvio (vedolizumab), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab), ustekinumab,
Tremfya (guselkumab), Xeljanz/Xeljanz XR (tofacitinib), Zeposia (ozanimod)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Omvoh will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Omvoh therapy
-AND-
(2) Patient is not receiving Omvoh in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Entyvio (vedolizumab), Olumiant (baricitinib), Orencia
(abatacept), Rinvoq (upadacitinib), Simponi (golimumab), Skyrizi
(risankizumab), ustekinumab, Tremfya (guselkumab), Xeljanz/Xeljanz XR
(tofacitinib), Zeposia (ozanimod)]
© 2025 UnitedHealthcare Services, Inc.
1
Authorization will be issued for 12 months.
B. Crohn’s Disease (CD)
1. Initial Authorization for Maintenance Dosing
a. Omvoh will be approved based on both of the following criteria:
(1) Diagnosis of moderately to severely active Crohn’s disease
-AND-
(2) Patient is not receiving Omvoh in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab-rzaa),
ustekinumab, Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
2. Reauthorization
a. Omvoh will be approved based on both of the following criteria:
(1) Documentation of positive clinical response to Omvoh therapy
-AND-
(2) Patient is not receiving Omvoh in combination with another targeted
immunomodulator [e.g., adalimumab, Cimzia (certolizumab), Enbrel
(etanercept), Olumiant (baricitinib), Orencia (abatacept), Rinvoq
(upadacitinib), Simponi (golimumab), Skyrizi (risankizumab-rzaa),
ustekinumab, Xeljanz (tofacitinib)]
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific
benefit plan coverage may also impact coverage criteria. Other policies and utilization
management programs may apply.
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
• The intravenous infusion is typically covered under the medical benefit. Please refer to the
UnitedHealthcare Drug Policy for Omvoh.
© 2025 UnitedHealthcare Services, Inc.
2
4. Reference:
1. Omvoh [package insert]. Indianapolis, IN: Eli Lilly and Company; January 2025.
Program Prior Authorization/Notification - Omvoh (mirikizumab-mrkz)
Change Control
1/2024 New program
1/2025 Annual review with no change to clinical criteria. Updated examples
with no change to clinical intent. Updated reference.
3/2025 Added coverage criteria for Crohn’s disease. Updated background and
reference.
© 2025 UnitedHealthcare Services, Inc.
3